Literature DB >> 6184486

Abelson murine leukemia virus P120: identification and characterization of tyrosine phosphorylation sites.

F H Reynolds, S Oroszlan, J R Stephenson.   

Abstract

Tryptic peptides containing two major in vivo P120gag-abl tyrosine phosphorylation acceptor sites were identified, phosphorylated in vitro, and purified to homogeneity. The tyrosine site in peptide a is localized at a position six residues distal to its trypsin cleavage site, whereas the tyrosine acceptor site in peptide b is at residue seven. A third peptide, c, contains an amino-terminal phosphotyrosine residue: phosphorylation of this latter peptide only occurs to a significant extent in vivo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184486      PMCID: PMC256374     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Direct transformation of 3T3 cells by Abelson murine leukaemia virus.

Authors:  C D Scher; R Siegler
Journal:  Nature       Date:  1975-02-27       Impact factor: 49.962

2.  In vitro transformation of lymphoid cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore; C D Scher
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

3.  Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells.

Authors:  O N Witte; N Rosenberg; M Paskind; A Shields; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

4.  Translation of type C viral RNAs in Xenopus laevis oocytes: evidence that the 120,000-molecular-weight polyprotein expressed in Abelson leukemia virus-transformed cells is virus coded.

Authors:  R K Reynolds; W J van de Ven; J R Stephenson
Journal:  J Virol       Date:  1978-11       Impact factor: 5.103

5.  Cells nonproductively transformed by Abelson murine leukemia virus express a high molecular weight polyprotein containing structural and nonstructural components.

Authors:  F H Reynolds; T L Sacks; D N Deobagkar; J R Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

6.  Lymphosarcoma: virus-induced thymic-independent disease in mice.

Authors:  H T Abelson; L S Rabstein
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

7.  Abelson murine leukaemia virus transformation involves loss of epidermal growth factor-binding sites.

Authors:  J Blomberg; F H Reynolds; W J Van de Ven; J R Stephenson
Journal:  Nature       Date:  1980-07-31       Impact factor: 49.962

8.  The nonstructural components of polyproteins encoded by replication-defective mammalian transforming retroviruses are phosphorylated and have associated protein kinase activity.

Authors:  W J Van de Ven; F H Reynolds; J R Stephenson
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

9.  The nonstructural component of the Abelson murine leukemia virus polyprotein P120 is encoded by newly acquired genetic sequences.

Authors:  W J Van de Ven; F H Reynolds; R P Nalewaik; J R Stephenson
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

10.  Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine.

Authors:  O N Witte; A Dasgupta; D Baltimore
Journal:  Nature       Date:  1980-02-28       Impact factor: 49.962

View more
  3 in total

1.  Active Akt and functional p53 modulate apoptosis in Abelson virus-transformed pre-B cells.

Authors:  Li Gong; Indira Unnikrishnan; Anuradha Raghavan; Kalindi Parmar; Naomi Rosenberg
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Altered subcellular distribution of c-Abl in Alzheimer's disease.

Authors:  Zheng Jing; John Caltagarone; Robert Bowser
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

3.  Isolation of temperature-sensitive tyrosine kinase mutants of v-abl oncogene by screening with antibodies for phosphotyrosine.

Authors:  E T Kipreos; G J Lee; J Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.